UNLABELLED: Primary biliary cirrhosis (PBC) is characterized by antimitochondrial antibodies (AMAs), directed to the E2 component of the pyruvate dehydrogenase complex (PDC-E2). Notwithstanding the presence of mitochondria in virtually all nucleated cells, the destruction in PBC is limited to small intrahepatic bile ducts. The reasons for this tissue specificity remain unknown, although biliary epithelial cells (BECs) uniquely preserve the PDC-E2 epitope following apoptosis. Notably, PBC recurs in an allogeneic transplanted liver, suggesting generic rather than host PBC-specific susceptibility of BEC. We used cultured human intrahepatic BECs (HIBECs) and other well-characterized cell lines, including, HeLa, CaCo-2 cells, and nontransformed human keratinocytes and bronchial epithelial cells, to determine the integrity and specific localization of PDC-E2 during induced apoptosis. All cell lines, both before and after apoptosis, were tested with sera from patients with PBC (n = 30), other autoimmune liver and rheumatic diseases (n = 20), and healthy individuals (n = 20) as well as with a mouse monoclonal antibody against PDC-E2 and AMA with an immunoglobulin A isotype. PDC-E2 was found to localize unmodified within apoptotic blebs of HIBECs, but not within blebs of various other cell lineages studied. The fact that AMA-containing sera reacted with PDC-E2 on apoptotic BECs without a requirement for permeabilization suggests that the autoantigen is accessible to the immune system during apoptosis. CONCLUSION: Our data indicate that the tissue (cholangiocyte) specificity of the autoimmune injury in PBC is a consequence of the unique characteristics of HIBECs during apoptosis and can be explained by exposure to the immune system of intact immunoreactive PDC-E2 within apoptotic blebs.
UNLABELLED: Primary biliary cirrhosis (PBC) is characterized by antimitochondrial antibodies (AMAs), directed to the E2 component of the pyruvate dehydrogenase complex (PDC-E2). Notwithstanding the presence of mitochondria in virtually all nucleated cells, the destruction in PBC is limited to small intrahepatic bile ducts. The reasons for this tissue specificity remain unknown, although biliary epithelial cells (BECs) uniquely preserve the PDC-E2 epitope following apoptosis. Notably, PBC recurs in an allogeneic transplanted liver, suggesting generic rather than host PBC-specific susceptibility of BEC. We used cultured human intrahepatic BECs (HIBECs) and other well-characterized cell lines, including, HeLa, CaCo-2 cells, and nontransformed human keratinocytes and bronchial epithelial cells, to determine the integrity and specific localization of PDC-E2 during induced apoptosis. All cell lines, both before and after apoptosis, were tested with sera from patients with PBC (n = 30), other autoimmune liver and rheumatic diseases (n = 20), and healthy individuals (n = 20) as well as with a mouse monoclonal antibody against PDC-E2 and AMA with an immunoglobulin A isotype. PDC-E2 was found to localize unmodified within apoptotic blebs of HIBECs, but not within blebs of various other cell lineages studied. The fact that AMA-containing sera reacted with PDC-E2 on apoptotic BECs without a requirement for permeabilization suggests that the autoantigen is accessible to the immune system during apoptosis. CONCLUSION: Our data indicate that the tissue (cholangiocyte) specificity of the autoimmune injury in PBC is a consequence of the unique characteristics of HIBECs during apoptosis and can be explained by exposure to the immune system of intact immunoreactive PDC-E2 within apoptotic blebs.
Authors: J Van de Water; L B Gerson; L D Ferrell; J R Lake; R L Coppel; K P Batts; R H Wiesner; M E Gershwin Journal: Hepatology Date: 1996-11 Impact factor: 17.425
Authors: P Invernizzi; A Crosignani; P M Battezzati; G Covini; G De Valle; A Larghi; M Zuin; M Podda Journal: Hepatology Date: 1997-05 Impact factor: 17.425
Authors: Burton Combes; Scott S Emerson; Nancy L Flye; Santiago J Munoz; Velimir A Luketic; Marlyn J Mayo; Timothy M McCashland; Rowen K Zetterman; Marion G Peters; Adrian M Di Bisceglie; Kent G Benner; Kris V Kowdley; Robert L Carithers; Leonard Rosoff; Guadalupe Garcia-Tsao; James L Boyer; Thomas D Boyer; Enrique J Martinez; Nathan M Bass; John R Lake; David S Barnes; Maurizio Bonacini; Karen L Lindsay; A Scott Mills; Rodney S Markin; Raphael Rubin; A Brian West; Donald E Wheeler; Melissa J Contos; Alan F Hofmann Journal: Hepatology Date: 2005-11 Impact factor: 17.425
Authors: Tin Ky Mao; Zhe-Xiong Lian; Carlo Selmi; Yasunori Ichiki; Paul Ashwood; Aftab A Ansari; Ross L Coppel; Shinji Shimoda; Hiromi Ishibashi; M Eric Gershwin Journal: Hepatology Date: 2005-10 Impact factor: 17.425
Authors: C Migliaccio; A Nishio; J Van de Water; A A Ansari; P S Leung; Y Nakanuma; R L Coppel; M E Gershwin Journal: J Immunol Date: 1998-11-15 Impact factor: 5.422
Authors: Michele M Tana; Zakera Shums; Jay Milo; Gary L Norman; Patrick S Leung; M Eric Gershwin; Mazen Noureddin; David E Kleiner; Xiongce Zhao; Theo Heller; Jay H Hoofnagle Journal: Am J Clin Pathol Date: 2015-10 Impact factor: 2.493
Authors: Patrick S C Leung; Jinjung Choi; Guoxiang Yang; Elena Woo; Thomas P Kenny; M Eric Gershwin Journal: Expert Rev Mol Diagn Date: 2016-03-30 Impact factor: 5.225
Authors: Wenting Huang; Kritika Kachapati; David Adams; Yuehong Wu; Patrick S C Leung; Guo-Xiang Yang; Weici Zhang; Aftab A Ansari; Richard A Flavell; M Eric Gershwin; William M Ridgway Journal: J Autoimmun Date: 2014-02-18 Impact factor: 7.094